Fidelity SPDR Advertisement
Home > Boards > US OTC > Medical - Drugs >

IntelGenx Technologies Corp. (IGXT)

IGXT RSS Feed
Add IGXT Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator ofspring, GaryJPalys, kyouter
Search This Board:
Last Post: 11/18/2014 8:17:08 AM - Followers: 185 - Board type: Free - Posts Today: 1

IntelGenx Technologies Corp

Listing Exchanges: OTCQX as IGXT and Toronto Venture Exchange: IGX.V

Current partners include, Edgemont Pharma, Pacific Therapeutics, Dava Pharmaceuticals, RedHill Biopharma, and PAR Pharmaceuticals. We are in discussions with other potential partners for some of our other products.

Our unique proprietary platform delivery technologies offer many benefits to our partners including:
Broad range of delivery profiles
Convenient and versatile products
High quality products


Business Strategy
Our business strategy is to apply our drug delivery technologies to improve existing drug compounds with proven efficacy and safety and, in conjunction with
strategic development and distribution partners, reintroduce these drug compounds to the market as branded products with improved deliverability and efficacy. 

Because we are developing improved formulations of currently marketed therapeutics, our products typically require fewer clinical trials to generate the safety and
efficacy data needed to achieve regulatory approval than drug formulations that have not been previously marketed. As a result, we believe we can accelerate
development and reduce risk compared to traditional pharmaceutical and biotechnology companies. 

Using the 505(b)(2) approach to obtain FDA approval, our products have the possibility of obtaining  three years of market exclusivity.



--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
 

IntelGenx (IGX / IGXT) Announces Commercial Launch of Forfivo XL(TM) in USA - Viral News



(Click the link below to watch video)

    Forfivotm XL Launch Video

 


(Click on picture below to go to website)
 




PharmaIntellect

Friday, October 5, 2012



Withdrawal of Teva's Budeprion XL 300 from the US market should benefit IntelGenx Technologies

USFDA has asked Teva to wihdraw - Budeprion XL 300 from the US.
  According to USFDA, Budeprion XL 300 is no bioequivalent to Welbutrin XL 300.
  It has been found that Budeprion XL 300 releases the active ingredient faster than the original drug Welbutrin XL 300.
The USFDA reviewed the Budeprion XL, after several patients complained 
about head aches, anxiety and insomnia.

We think the withdrawal can be positive for IntelGenx
which is preparing to launchForfivo ( bupropion extended release 450mg)
and should help the launch trajectory for Forfivo. 
Forfivo will be marketed by Edgemont pharmaceuticals in the US.
Edgemont focuses exclusively on launching specialty drugs aimed at the neuropsychiatry sector,
and has one drug on the market - high-dose fluoxetine (Prozac).


Forfivo is the only single tablet that is formulated to deliver a dose of 450mg.
Until now, those patients who need to take the highest dose (450mg)
of bupropion XL need to take multiple tablets of lower-strength doses as there.


Market Opportunity

In 2011, total branded and generic sales of extended-release bupropion
totaled $745 million, of which 
roughly 20% was for the highest dose (450mg).


------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



IntelGenX Corporate Presentation September 2014

Click on the image below
 
September, 2014

 

 




                                    

 




 
March 12th, 2012 -   Cleland Fund comments regarding their investment insight for IGXT: 

March 12, 2012 -   BluMont Capital Corporation - Northern Rivers Funds - 70 University Avenue - Suite 1200, PO Box 16 - Toronto, ON M5J 2M4 - Canada - Tel: 416.597.1226 - Fax: 416.597.8926

The Northern Rivers Innovation RSP Fund ("the Innovation Fund" or "the Fund") Dear Partners and Friends: Let's go through the major holdings…(Below is just the IGXT portion)

INTELGENX: FDA approval for their 1st drug in November + a commercialization partner for that drug + a deal with Par Pharmaceuticals = lower share price??? This is a completely irrational situation, making IntelGenx a table pounder. As of the close on March 7, the stock is LOWER than it was before CPI-300 (IntelGenx' antidepressant) received FDA approval; LOWER than it was before the deal with Par Pharmaceutical; and LOWER than it was before the announcement of its commercialization partner for CPI-300. I would argue that at $0.55 or lower, the only thing an investor is paying for is CPI-300, meaning that you are getting the entire thin-film delivery platform and 9 drug pipelines for FREE. Notably, there are only a handful of thin-film companies out there, and IntelGenx is one of only two that are publicly traded (that I am aware of). As thin-films become more recognized for their value to big pharma over the coming years, the scarcity value of thin-film platforms will ultimately result in IntelGenx' thin-film platform and pipeline receiving a premium valuation; right now, there is NO value. Ridiculous. I have put my money where my mouth is recently, and bought shares in the open market for the second of the two funds I run. To a certain degree, however, I understand what has happened: there was (unbeknownst to me or management) a scummy promote on IntelGenx last summer, in which CPI-300 was hyped as a billion dollar drug. Anyone who knows anything about CPI-300 and its market knows that that is complete crap. In fact, CPI-300 is the smallest revenue potential drug within IntelGenx' pipeline, with peak revenue to Intelgenx' commercialization partner maybe in the $60-$100million range. This means that reality has been a big let-down to those who bought into the billion dollar dream. But the fact is that the commercialization deal and FDA approval for CPI-300 do two very important things for IntelGenx: 1) Getting CPI-300 approved by the FDA provided concrete illustration that IntelGenx has the skill set to negotiate the 505b2 pathway to drug approval, which involves both dealing with the FDA and dealing with the court system. For me, that validation will ultimately lower the discount rate that is applied to the rest of IntelGenx' pipeline. 2) The upfront, milestone and royalty payments from the commercialization deal for CPI-300 arguably cover all of IntelGenx' development costs for its pipeline of thin-film 505b2 drugs. If this sounds far-fetched, recall that the 505b2 pathway to drug approval is dramatically different than the conventional PhaseI-II-III pathway, because IntelGenx is simply moving existing, already-FDA-approved drugs onto a different delivery platform. i.e., IntelGenx is working on projects such as moving Cialis and a migraine drug onto a thin-film platform. It is a cheap, and extremely low-risk pathway to getting a drug to market. The CPI-300 deal with Edgemont Pharmaceuticals: a source of disappointment for the market; a source of confidence for me On February 14, IntelGenx announced a commercial license agreement for CPI-300 with Edgemont Pharmaceuticals. The deal provided for $1M upfront for IntelGenx and a series of milestones that could reach $28.5M over the life of the agreement. According to the company up to $4M of these milestones are achievable at the product launch or shortly thereafter. IntelGenx is also entitled to a double digit royalty on net product sales. The market reaction thus far to the deal has been negative. It seems many people were perhaps speculating on a more prominent partner and/or better economics in the deal. However, I think the markets have misinterpreted the quality of the deal, I think in part due to misjudging Edgemont but also misunderstanding what CPI-300 means to IntelGenx. On the former, Edgemont is a smaller private company that has very little visibility to people outside the industry. But a closer inspection reveals a company with a sales and marketing focus on neurology, a CEO who formerly ran Novartis' CNS business in the US, and a Board populated with people from some of the most successful U.S. specialty pharma companies of the past 15 years. This last point is one of the nuances that the markets really seem to have missed. Two of the Edgemont Board members are former Kos Pharmaceuticals (formerly Nasdaq: KOSP) executives who now work for a private equity firm called Vatera Capital. For anyone who hasn't heard of Kos, they were arguably the most successful specialty pharma company in the U.S. in the past 15 years. They created a market for a prescription vitamin called Niaspan, which paved the way for future prescription vitamin and omega-3 companies like Reliant, Amarin and Neptune/Acasti. Kos was eventually bought by Abbott for $3.7B, and one of the founders Michael Jaharis took his money (he is estimated now to be worth $1.9B) and formed Vatera Capital to invest in businesses like Edgemont. So Vatera's investment in Edgemont gives me tremendous confidence that IntelGenx has landed a great partner who has the marketing savvy and financial backing to extract the most value out of CPI-300. That leads me to my second point regarding the significance of this deal to IntelGenx: In my opinion CPI-300 will provide IntelGenx the financial platform to aggressively accelerate and expand its pharmaceutical thin-film business. Thin-films are the big opportunity in IntelGenx' portfolio. Whether it is drugs for erectile dysfunction, insomnia or migraine, each of these products represent bigger opportunities for IntelGenx than CPI-300. With Reckitt Benckiser's suboxone film (one of only two FDA approved thin films) apparently trending toward $1B in annual sales, it is clear that the market and FDA are receptive to this new delivery system. Fortunately IntelGenx has a number of products through pilot human studies and one product (migraine) due to enter pivotal studies shortly, so they would appear to be well positioned with a number of nearer term thin-film projects. With all this in mind, I believe that Edgemont and CPI-300 provide a means to a much more lucrative end, that being IntelGenx becoming the world leader in the growing area of thin film drug delivery and development.

 

 
                                                                                                                                                                                  The following info is now based on IGXT's own SEC filings
                                                                                                                                                                     

Industry: Bio-technology

Market Capitalization: 23.55 Million 

Issued Shares: 63.1 Million

Fully Diluted Shares: 72 Million

Float Shares: 56.9 Million

Insider and Institutional Ownership: 18% 



 

Latest News

  •                                                                                                                                                                                                                                                                        (Click on Date for link to news article)
2014-07-15

Intelgenx Announces Management Changes



2014-07-01
 

Intelgenx Announces Equity Analyst Coverage by H.C. Wainwright


2014-05-21
 

Intelgenx and RedHill Biopharma Report Positive Bioavailability Study Results in Support of Planned European Marketing Application in Q3/2014 for Anti-Migraine VersaFilm(TM) Product


2014-05-13
 

Intelgenx Reports Q1 2014 results and provides corporate developement update



2014-04-30
 

Intelgenx Announces government of canada funding for cNS VersaFilm(TM) project



2014-04-28
 

Intelgenx and Redhill Biopharma Announce Commencement of a Bioavailability Study with Anti-Migraine VersaFilm(TM) Product to support european marketing application planned for q3/2014



2014-04-24
 

Intelgenx

and RedHill Biopharma Provide an Update on FDA's Ongoing Review of the NDA for Migraine VersaFilm(TM) Product


2014-04-16
 

Intelgenx Announces Receipt of an Additional U.S. Patent Allowance Related To Proprietary Technology


2014-03-03
 

Intelgenx and RedHill Biopharma Submit Response to FDA CRL for VersaFilm(TM) Product for Migraines


2014-02-24
 

Intelgenx Achieves Positive Bioequivalence Results for Erectile Dysfunction VersaFilm

2014-01-13


IntelGenx Announces Additional Developement and Commercialization with Par for Two More Products


2013-08-26


IntelGenx Corp. Receives Buprenorphine/Naloxone Sublingual Film Product Patent Infringement Complaint


2013-08-22
 

IntelGenx Receives Paragraph IV Certification Letter on Submission of ANDA for Forfivo XL™


2013-08-08

IntelGenx Reports Q2, 2013 Results and Corporate Development Highlights


2013-07-25

Time To Revalue IntelGenx- 2 More Products Being Reviewed By The FDA For Approval


2013-07-22

Intelgenx

Announces Submission of ANDA for Buprenorphine/Naloxone Sublingual Film Product for the Treatment of Opiate Addiction


2013-06-27


Small-Cap Biotechs with Blockbuster Potential: Hugh Cleland


2013-06-18


IntelGenx Announces FDA Acceptance of New Drug Application for Anti-Migraine VersaFilm(TM) Oral Film Product


2013-05-14


IntelGenx Reports Q1, 2013 Results and Provides Operational Update


2013-04-24


IntelGenx secures leadership Succession


2013-03-27


IntelGenx submits New Drug Application for Anti-Migraine VersaFilm(TM)


2012-10-09 
   

IntelGenx Announces Commercial Launch of Forfivo XL(TM) in USA


2012-08-07

 
  IntelGenx Reports Second Quarter 2012 Results and Highlights Recent Developments
 

                                                                                                                                                                 

IGXT Website: http://www.intelgenx.com/index.html




 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IGXT
Current Price
Volume:
Bid Ask Day's Range
Wiki
IGXT News: Quarterly Report (10-q) 11/12/2014 08:03:10 AM
IGXT News: Current Report Filing (8-k) 11/03/2014 08:22:51 AM
IGXT News: Current Report Filing (8-k) 10/02/2014 08:10:28 AM
IGXT News: Current Report Filing (8-k) 10/01/2014 08:18:11 AM
IGXT News: Current Report Filing (8-k) 09/17/2014 10:01:01 AM
PostSubject
#10894  Sticky Note IntelGenx (OTCQX:IGXT) Announces Successful Clinical Study for Schizophrenia Stockmountie 11/03/14 08:09:19 AM
#10886  Sticky Note IGXT is a garbage pipedream penny stock for ofspring 10/26/14 07:02:35 PM
#10517  Sticky Note IntelGenx (TSX-V:IGX) (OTCQX:IGXT) and RedHill Biopharma Report Stockmountie 05/21/14 08:09:54 AM
#10936   IGXT up 10% today on above average volume .... chemist72 11/20/14 03:46:57 PM
#10935   IntelGenx (IGXT) to Present at Singular Research's Best Stockmountie 11/18/14 08:17:08 AM
#10934   I am watching this one close, would like mentalist 11/17/14 12:32:33 PM
#10933   Next year and next year and next year .... chemist72 11/17/14 09:00:42 AM
#10932   Check out how the accumulation line has (is jevansac 11/15/14 12:06:02 PM
#10931   "Of the total revenue recorded during the first jevansac 11/15/14 11:48:21 AM
#10930   Why all the doom and gloom? Some may jevansac 11/15/14 11:33:10 AM
#10929   Interesting? Ok... I will always take a interest GaryJPalys 11/14/14 06:06:57 PM
#10928   Yet you still keep posting on this board, interesting. jamesrock 11/14/14 04:17:51 PM
#10927   3½ hours into the trade day and we GaryJPalys 11/14/14 01:04:07 PM
#10926   Can't say it was a good report, but specular 11/12/14 04:55:45 PM
#10925   Got to say it, CEO killed the company. mentalist 11/12/14 02:22:24 PM
#10924   Forfivo issues have been on the execution side, specular 11/12/14 11:39:15 AM
#10923   "Management anticipates that sales of Forfivo XL(R) will chemist72 11/12/14 09:06:38 AM
#10922   IntelGenx (IGXT) Reports Q3, 2014 Results and Provides Stockmountie 11/12/14 08:06:38 AM
#10921   Yes they do mention the Migraine drug, particularly specular 11/11/14 10:52:12 AM
#10920   Any mention on Rizaport (migraine)for the FDA issue? kyouter 11/11/14 10:07:28 AM
#10919   Nice to see Zerbe teaming up with such specular 11/10/14 04:16:50 PM
#10918   Is there still a cooperation between Intelgenx and DAVA? Polonia 11/10/14 03:59:30 PM
#10917   Ha? I live in Norway. Dont know if Polonia 11/10/14 03:56:19 PM
#10916   which is why you didn't win the world cup. specular 11/10/14 03:51:45 PM
#10915   In my country we say that "the best" Polonia 11/10/14 01:07:20 PM
#10914   Which means.. kyouter 11/10/14 11:53:44 AM
#10913   We should expect a bad report tomorrow. specular 11/09/14 09:36:42 PM
#10912   Q3 tomorrow..10th nov.. Polonia 11/09/14 11:58:13 AM
#10911   Plus no sales to speak of - no specular 11/07/14 12:14:36 PM
#10910   Sure does... But at least they have no GaryJPalys 11/07/14 11:45:15 AM
#10909   The issue on the Migraine is that they specular 11/07/14 10:40:08 AM
#10907   Pos just keeps going down... ofspring 11/07/14 10:33:18 AM
#10906   Yeah, I think most CEO's seem to forget GaryJPalys 11/06/14 05:10:51 PM
#10905   I agree but disagree, I think if he mentalist 11/06/14 12:21:50 PM
#10904   what's with the continued paid pumps anyways? kyouter 11/06/14 11:43:28 AM
#10903   in line with being listed... kyouter 11/06/14 11:22:06 AM
#10902   His incompetence on the raw material supply for specular 11/06/14 10:45:14 AM
#10901   Very sad indeed, I have no idea why mentalist 11/06/14 06:41:04 AM
#10900   I keep expecting to see a new filing GaryJPalys 11/05/14 05:00:44 PM
#10899   I'm glad I only have pocket change in GaryJPalys 11/05/14 04:58:21 PM
#10898   His paranoid. Polonia 11/05/14 04:51:42 PM
#10897   $5M cash and cash equivalents as of June chemist72 11/05/14 01:37:05 PM
#10896   And the bleeding continues... kyouter 11/05/14 12:55:59 PM
#10895   If it follows the usual script, we should specular 11/05/14 12:13:00 PM
#10894   IntelGenx (OTCQX:IGXT) Announces Successful Clinical Study for Schizophrenia Stockmountie 11/03/14 08:09:19 AM
#10893   Give the guy a break! kyouter 10/31/14 12:37:09 PM
#10892   The actual numbers are almost irrelevant - what specular 10/31/14 10:14:13 AM
#10891   Hmm... No, I was wrong about that! Maybe GaryJPalys 10/30/14 05:54:29 PM
#10890   They are always released on a Friday, so GaryJPalys 10/30/14 05:51:51 PM
#10889   I got reply from Paul: Polonia 10/30/14 04:39:55 PM
#10888   Should be first or second week of November... GaryJPalys 10/30/14 04:35:42 PM
#10887   Hi, anybody know the finacial kalender? Polonia 10/30/14 04:13:11 PM
#10886   IGXT is a garbage pipedream penny stock for ofspring 10/26/14 07:02:35 PM
PostSubject